https://doi.org/10.55788/0b34fe19
Nitroglycerin can be used to induce a migraine-like symptomatology in laboratory mice, which can be efficiently treated with available migraine medication [1]. “After induction, we looked at the acute effect of sumatriptan and chronic effect of topiramate before looking at the treatment effect of an anti-PACAP antibody,” said Dr Charlotte Ernstsen Lauritzen (H. Lundbeck A/S, Denmark) [2]. “We also assessed possible vestibular effects using the balanced beam assay and looked at potential meningeal vasodilation in awake and freely moving mice.”
In a first substudy, nitroglycerin induced acute mechanical hypersensitivity on day 1, which both sumatriptan and topiramate could block: there was a significantly lower 50% mechanical sensitivity in the sumatriptan plus nitroglycerin, topiramate plus nitroglycerin, and vehicle control groups, compared with nitroglycerin alone. In a similar substudy, topiramate (administered daily for 9 days) also blocked chronic nitroglycerin-induced mechanical hypersensitivity. Further to these results, an anti-PACAP antibody blocked the mechanical hypersensitivity induced by nitroglycerin, both in an acute (day 1) and chronic (day 9) model (P<0.005 for both). In the balanced beam assay, acute nitroglycerin led to an increased time for animals to cross a balance beam, while chronic nitroglycerin increased the foot count on the beam (P<0.05 for both). Finally, longitudinal assessment of meningeal vasodilation showed enhanced changes from day 1 to day 9 in nitroglycerin-treated mice (P<0.05) but not in vehicle-treated mice (not significant).
“In summary, we confirmed that nitroglycerin induced mechanical hypersensitivity, and most notably, we saw that this could be blocked acutely and chronically with an anti-PACAP antibody,” said Dr Ernstsen Lauritzen. “We saw that nitroglycerin affects dynamic balance, which could be relevant in vestibular migraine studies. We also saw that both acute and chronic nitroglycerin administration induces vasodilation of meningeal arteries, with chronic nitroglycerin leading to enhanced dilation, suggesting migraine-like sensitisation in disease-relevant tissues.”
- Pradhan AA, et al. Pain. 2014 Feb;155(2):269-274.
- Ernstsen Lauritzen C, et al. Pharmaceutical insights into nitroglycerin effects on meningeal blood vessel imaging, sensory threshold, and motor function in mice. 18th European Headache Congress, 4–7 December 2024, Rotterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Rimegepant reduces migraine symptoms through 1 year of treatment Next Article
Cabergoline is a potential add-on treatment option in patients with migraine »
« Rimegepant reduces migraine symptoms through 1 year of treatment Next Article
Cabergoline is a potential add-on treatment option in patients with migraine »
Table of Contents: EHC 2024
Featured articles
More education on migraine features is needed
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Understanding Migraine Mechanisms
The locus coeruleus is involved in processing pain in migraine
Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura
Central arterial stiffness is involved in the pathophysiology of reversible cerebral vasoconstriction syndrome
Diagnostic and Predictive Tools
AI can enhance migraine diagnosis using easy-to-measure clinical data
New tool adequately captures multiple pain types in trigeminal neuralgia
MRI analyses suggest that migraine is not associated with altered brain white matter
More education on migraine features is needed
Treatment Innovations
PACAP-targeting therapies: a future option for migraine?
Rapid complete responses with atogepant
Cabergoline is a potential add-on treatment option in patients with migraine
Nitroglycerin-induced migraine targetable by different agents
Rimegepant reduces migraine symptoms through 1 year of treatment
Fremanezumab is a treatment option for paediatric patients with episodic migraine
What brain changes are associated with fremanezumab treatment success?
Preventative Therapies in Real-world Context
Low discontinuation rates with preventative galcanezumab in a real-world setting
Side effects are the main culprit for treatment discontinuation in indomethacin-sensitive headache disorders
Biofeedback training can reduce affected days in episodic migraine
Virtual reality interventions can reduce pain perception of chronic headache
Risk Factors and Long-term Management
Can predisposing factors be targeted to reduce new migraine incidence?
Active migraine comes at a high cost in Spain
Many patients, including non-responders, prefer triptans over non-headache-specific medication
Systemic Conditions and Migraine
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments
Related Articles
March 15, 2019
Lessons learned from triptan therapy
November 8, 2021
First real-world effectiveness data of erenumab is promising
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
